Australia | AI-powered Medical Devices: Tipping the scales in favour of patent eligibility
Key takeaways The Australian regulatory framework for medical devices provides useful, practical guidance for patenting inventions involving Artificial Intelligence (AI) within the medical technology (medtech) space. Whilst there is no statutory...
Key takeaways The Australian regulatory framework for medical devices provides useful, practical guidance for patenting inventions involving Artificial Intelligence (AI)...
Read More
China | Establishing Inventive Step in Swiss-Type Use Claims – A Case Study on Disease Subtypes and Known APIs
As pharmaceutical innovation increasingly targets specific disease subtypes and personalised therapies, patent protection strategies must evolve accordingly—especially in jurisdictions like China, where method of treatment claims are not patentable. This...
As pharmaceutical innovation increasingly targets specific disease subtypes and personalised therapies, patent protection strategies must evolve accordingly—especially in jurisdictions...
Read More
China | Good faith principle for patent applications
The principle of ‘good faith’ plays a crucial role in ensuring the integrity and reliability of patent applications. This principle is particularly emphasised in China's patent law, where adherence...
The principle of ‘good faith’ plays a crucial role in ensuring the integrity and reliability of patent applications. This...
Read More
Australia | Sanofi v Amgen dispute update
Federal Court dismisses Sanofi’s appeal and orders that Amgen’s Repatha patent applications proceed to grant, offering key lessons for other antibody patents approaching the end of their term. The global...
Federal Court dismisses Sanofi’s appeal and orders that Amgen’s Repatha patent applications proceed to grant, offering key lessons for...
Read More
Pharmaceutical Patent disputes in China | The nuances of “offer to sell”
The application of Bolar exceptions and the definition of "offer to sell" have long been contentious issues in the pharmaceutical industry in China. Article 11 of the Chinese Patent Law...
The application of Bolar exceptions and the definition of "offer to sell" have long been contentious issues in the pharmaceutical...
Read More